Amoxicillin
- Generic Name
- Amoxicillin
- Brand Names
- Amoxil, Augmentin, Clavulin, Moxatag, Omeclamox, Prevpac, Talicia, Voquezna 14 Day Dualpak 20;500, Voquezna 14 Day Triplepak 20;500;500
- Drug Type
- Small Molecule
- Chemical Formula
- C16H19N3O5S
- CAS Number
- 26787-78-0
- Unique Ingredient Identifier
- 9EM05410Q9
- Background
Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin has similar activity to penicillin and ampicillin, but leads to higher serum concentrations than ampicillin.
Amoxicillin was granted FDA approval on 18 January 1974.
- Indication
Amoxicillin alone is indicated to treat susceptible bacterial infections of the ear, nose, throat, genitourinary tract, skin, skin structure, and lower respiratory tract. Amoxicillin is given with calvulanic acid to treat acute bacterial sinusitis, community acquired pneumonia, lower respiratory tract infections, acute bacterial otitis media, skin and skin s...
- Associated Conditions
- Acute Bacterial Sinusitis (ABS), Acute Otitis Media (AOM), Bacterial Infections, Community Acquired Pneumonia (CAP), Duodenal ulcer caused by helicobacter pylori, Genitourinary tract infection, Helicobacter Pylori Infection, Lower Respiratory Tract Infection (LRTI), Peptic Ulcer With H. Pylori Infection, Sinusitis, Skin and Subcutaneous Tissue Bacterial Infections, Urinary Tract Infection, Acute, uncomplicated Gonorrhea, Ear, nose, and throat infections
- Associated Therapies
- -
Study on The Efficacy and Safety of Berberine-containing Triple Therapy in Helicobacter Pylori First-Line Eradication
- Conditions
- Interventions
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- Xijing Hospital of Digestive Diseases
- Target Recruit Count
- 300
- Registration Number
- NCT05014334
- Locations
- 🇨🇳
Xijing Hosipital of Digestive Disease, Xi'an, Shaanxi, China
PPI-amoxicillin for H. Pylori Treatment
- Conditions
- Interventions
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 732
- Registration Number
- NCT05014685
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Penicillin De-labeling in the Pediatric Primary Care Setting
- First Posted Date
- 2021-08-18
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 23
- Registration Number
- NCT05010304
- Locations
- 🇺🇸
Children's Medical Center Dallas, Dallas, Texas, United States
Procalcitonin to Reduce Antibiotic Use in Pediatric Pneumonia
- Conditions
- Interventions
- First Posted Date
- 2021-07-15
- Last Posted Date
- 2024-02-15
- Target Recruit Count
- 5
- Registration Number
- NCT04963764
- Locations
- 🇺🇸
Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Outcome of Patients After a Negative Oral Challenge to Amoxicillin
- Conditions
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- University Hospital, Angers
- Target Recruit Count
- 190
- Registration Number
- NCT04922034
- Locations
- 🇫🇷
CHU, Angers, Maine Et Loire, France
Oral Amoxicillin and Cephalexin PK/PD in Neonates
- First Posted Date
- 2021-06-08
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 60
- Registration Number
- NCT04916951
- Locations
- 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
Efficacy and Safety of Vonoprazan as First-line Treatment for Helicobacter Pylori Eradication
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2021-06-01
- Target Recruit Count
- 234
- Registration Number
- NCT04907747
- Locations
- 🇨🇳
Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China
Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days
- First Posted Date
- 2021-05-25
- Last Posted Date
- 2021-05-25
- Lead Sponsor
- Shandong University
- Target Recruit Count
- 1300
- Registration Number
- NCT04901117
- Locations
- 🇨🇳
Qilu hosipital, Jinan, Shandong, China
A Study of Vonoprazan in Adults With Helicobacter Pylori
- Conditions
- Interventions
- First Posted Date
- 2021-02-15
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- Takeda
- Target Recruit Count
- 44
- Registration Number
- NCT04753437
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Phase I Unit, Chengdu, Sichuan, China
The Effect of Dual Eradication Therapy vs PPI on Gastrointestinal Bleeding in ACS Patients
- First Posted Date
- 2021-01-28
- Last Posted Date
- 2021-08-03
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 2600
- Registration Number
- NCT04728516
- Locations
- 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China
🇨🇳Qilu Hospital of Shandong University (Qingdao), Qingdao, Shandong, China
🇨🇳The Ninth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.